JP2024502598A - ケタミンの経口投与 - Google Patents

ケタミンの経口投与 Download PDF

Info

Publication number
JP2024502598A
JP2024502598A JP2023541536A JP2023541536A JP2024502598A JP 2024502598 A JP2024502598 A JP 2024502598A JP 2023541536 A JP2023541536 A JP 2023541536A JP 2023541536 A JP2023541536 A JP 2023541536A JP 2024502598 A JP2024502598 A JP 2024502598A
Authority
JP
Japan
Prior art keywords
ketamine
aspirin
composition
oral
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502598A5 (cg-RX-API-DMAC7.html
Inventor
ジョゼフ ハブーシュ,
Original Assignee
ヴィタリス アナルジージックス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィタリス アナルジージックス エルエルシー filed Critical ヴィタリス アナルジージックス エルエルシー
Publication of JP2024502598A publication Critical patent/JP2024502598A/ja
Publication of JP2024502598A5 publication Critical patent/JP2024502598A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023541536A 2021-01-08 2022-01-07 ケタミンの経口投与 Pending JP2024502598A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163135126P 2021-01-08 2021-01-08
US63/135,126 2021-01-08
US202163176654P 2021-04-19 2021-04-19
US63/176,654 2021-04-19
US202163235413P 2021-08-20 2021-08-20
US63/235,413 2021-08-20
PCT/US2022/011630 WO2022150597A1 (en) 2021-01-08 2022-01-07 Oral administration of ketamine

Publications (2)

Publication Number Publication Date
JP2024502598A true JP2024502598A (ja) 2024-01-22
JP2024502598A5 JP2024502598A5 (cg-RX-API-DMAC7.html) 2025-01-16

Family

ID=82323518

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541536A Pending JP2024502598A (ja) 2021-01-08 2022-01-07 ケタミンの経口投与

Country Status (4)

Country Link
US (2) US11382873B1 (cg-RX-API-DMAC7.html)
EP (1) EP4274557A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024502598A (cg-RX-API-DMAC7.html)
WO (1) WO2022150597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3505157T3 (da) 2017-12-29 2022-02-28 Celon Pharma Sa Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression
US20240009145A1 (en) * 2022-07-07 2024-01-11 Vitalis Analgesics LLC Compositions of aspirin and ketamine
WO2025160483A1 (en) * 2024-01-24 2025-07-31 Awakn Ls Europe Holdings Limited Oral transmucosal esketamine therapy for alcohol use disorder and substance use disorders

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP2009543875A (ja) * 2006-07-19 2009-12-10 ワトソン ラボラトリーズ、インコーポレイテッド 制御性放出製剤および関連する方法
JP2010532358A (ja) * 2007-07-01 2010-10-07 ピーター ハバウシ,ジョセフ 咀嚼可能外層を有する配合剤
WO2018102488A1 (en) * 2016-11-30 2018-06-07 Wolfson Philip E Ketamine for the treatment of menstrually related symptoms
WO2020086673A1 (en) * 2018-10-26 2020-04-30 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
CN107669649A (zh) * 2012-10-11 2018-02-09 Ix生物制药有限公司 固体剂型
KR20220044380A (ko) * 2013-04-12 2022-04-07 이칸 스쿨 오브 메디슨 엣 마운트 시나이 외상후 스트레스 장애의 치료 방법
US20150072005A1 (en) * 2013-09-10 2015-03-12 Vitalis Llc Aspirin formulation for increased efficacy
US11471415B2 (en) * 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
CN114805139B (zh) * 2018-01-10 2023-10-20 凯瑞康宁生物工程(武汉)有限公司 氯胺酮的前药、其组合物和用途
AU2019447630A1 (en) * 2019-05-31 2021-12-23 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
US20210308075A1 (en) * 2020-04-07 2021-10-07 Joseph Habboushe Prevention and treatment of virial infections

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
JP2009543875A (ja) * 2006-07-19 2009-12-10 ワトソン ラボラトリーズ、インコーポレイテッド 制御性放出製剤および関連する方法
JP2010532358A (ja) * 2007-07-01 2010-10-07 ピーター ハバウシ,ジョセフ 咀嚼可能外層を有する配合剤
WO2018102488A1 (en) * 2016-11-30 2018-06-07 Wolfson Philip E Ketamine for the treatment of menstrually related symptoms
WO2020086673A1 (en) * 2018-10-26 2020-04-30 Guangzhou Dazhou Biomedicine Ltd. Ketamine oral transmucosal delivery system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLINE, A. E. AND TURRENTINE, J. E.: "Compounded Topical Analgesics for Chronic Pain", DERMATITIS, vol. 27, no. 5, JPN6026012253, 2016, pages 263 - 271, ISSN: 0005826419 *
RAPEPORT, D. A. ET AL.: "The Use of "Ketofol" (Ketamine-propofol Admixture) Infusion in Conjunction with Regional Anaesthes", ANAESTHESIA AND INTENSIVE CARE, vol. 37, no. 1, JPN6026012252, 2009, pages 121 - 123, ISSN: 0005826418 *

Also Published As

Publication number Publication date
WO2022150597A1 (en) 2022-07-14
US20230077183A1 (en) 2023-03-09
US11382873B1 (en) 2022-07-12
EP4274557A1 (en) 2023-11-15
US20220218626A1 (en) 2022-07-14
EP4274557A4 (en) 2024-12-25
US12691082B2 (en) 2026-07-28

Similar Documents

Publication Publication Date Title
US20070059361A1 (en) Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20230077183A1 (en) Oral administration of ketamine
US20230225994A1 (en) Sublingual epinephrine formulations and methods of use
US20180228797A1 (en) Pharmaceutical compositions
TW202317101A (zh) 治療抑鬱狀態之方法
US20230338367A1 (en) Treatment of prurigo nodularis
US20130274342A1 (en) Compositions and methods for treating cough
JP2023545372A (ja) デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
ES2671926T3 (es) Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico
US20250099402A1 (en) Compositions of aspirin and ketamine
CN112703000B (zh) 慢性咳嗽、呼吸急促和呼吸困难的治疗
JP2006508122A (ja) チザニジンの頬及び舌下デリバリーのための医薬組成物及び投与形態並びにチザニジンを舌下又は頬に投与する方法
EP2248516A1 (en) Orally disintegrating compositions of emoxypine
JP7656339B2 (ja) 疼痛を緩和するためのイブプロフェン及びトラマドールの組合せ
JP2026515132A (ja) 抑うつ状態を治療するための方法
HK40109451A (en) Treatment of chronic cough, breathlessness and dyspnea
TW201434495A (zh) 阿戈美拉汀(agomelatine)之頰給藥之固態醫藥組合物
HK40067137A (en) Combination of ibuprofen and tramadol for relieving pain
HK40067137B (en) Combination of ibuprofen and tramadol for relieving pain
JP2013032408A (ja) 口中溶解型又は咀嚼型鼻炎治療用固形内服医薬組成物
HK40045293B (en) Treatment of chronic cough, breathlessness and dyspnea

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250107

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260626